The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments

REPORT HIGHLIGHTS

The projected U.S. market for biodefense-related rapid pathogen detection devices is valued at $214.2 million in 2015. The total market is projected to grow at a compound annual growth rate (CAGR) of 8% from 2016 through 2021 and reach $248 million by 2016 and $364 million by 2021.

This report provides:

• An overview of biodefense-related rapid pathogen identification and treatment markets, with a concentration on activities within the U.S.
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
• Identification of substances that can be weaponized for either cilivilian or military destruction rapidly and accurately.
• Information on infectious agents including smallpox, anthrax, plague and tularemia, as well as coverage of potentially harmful chemical toxins that are used in biological warfare situtations including sarin gas, ricin and botulinum.
• Outlines of the political and social landscape of biodefense, focusing on the issues of survelliance, coordination of resources and financing.
• Profiles of major players in the industry.

SCOPE AND FORMAT

The market report organizes information from diverse sources into a cohesive unit that includes an industry overview; overview of infectious agents with detection, vaccine and treatment information; biodefense-related diagnostic tools; current research and emerging industries related to rapid pathogen identification; biodefense-related pathogen identification product patents; and a comprehensive directory of assay, sensor, vaccine and treatment companies.

ANALYST'S CREDENTIALS

Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she has specialized in marketing reports on the medical industry for 20 years.

Table of Contents

CHAPTER 1 - INTRODUCTION

• REASONS FOR DOING THE STUDY
• STUDY GOALS AND OBJECTIVES
• INTENDED AUDIENCE
• SCOPE AND FORMAT
• METHODOLOGIES AND INFORMATION SOURCES
• ANALYST'S CREDENTIALS
• RELATED BCC RESEARCH REPORTS
• BCC RESEARCH WEBSITE
• DISCLAIMER

CHAPTER 2 - SUMMARY

• DETECTION
  • HANDHELD DEVICES
• TREATMENT
• CONTRIBUTING FACTORS TO BIODEFENSE-RELATED PATHOGEN IDENTIFICATION MARKET
• U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS
  • SUMMARY TABLE: U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE: BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION MARKET, BY TYPE OF DETECTION, IN 2016 AND 2021 (%)

CHAPTER 3 - INDUSTRY OVERVIEW

• HISTORY AND CURRENT STATE OF RAPID PATHOGEN IDENTIFICATION AND TREATMENTS
• DELIVERY AND DETECTION
  • AIRBORNE
  • EXPLOSIVES
  • FOOD AND WATER CONTAMINATION
  • ABSORPTION OR INJECTION
• POTENTIAL BIOLOGICAL PATHOGENS
  • CLASS A
    • TABLE 1: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS A
    • TABLE 2: CLASS A PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
  • CLASS B
    • TABLE 3: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS B
    • TABLE 4: CLASS B PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
  • CLASS C
    • TABLE 5: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS C
    • TABLE 6: CLASS C PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
• RAPID IDENTIFICATION PRODUCTS
  • TABLE 7: LIMITATIONS OF SOME COMMON ANALYSIS METHODS
• PCR
• QPCR
• MICROARRAY
• MASS SPECTROMETRY
• IMMUNOMAGNETIC SEPARATION (IMS)
• SENSING TECHNOLOGY
  • TABLE 8: CHARACTERISTICS OF BIOSENSORS
• FLUCTUATION-ENHANCING SENSING (FES)
• SENSING OF PHAGE-TRIGGERED ION CASCADES (SEPTIC)
• NANOPORE
• IMMUNOASSAY
  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Lateral Flow Tests
• DETECT-TO-WARN SYSTEMS
  • TABLE 9: DETECT-TO-WARN MONITORING SYSTEMS
• TREATMENTS
  • VACCINES
    • TABLE 10: VACCINES FOR PATHOGENS, BY DISEASE OR CONDITION, BRAND NAME AND MANUFACTURER, 2014
  • PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS
    • TABLE 11: COMMON PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS BY NAME, MANUFACTURER, DISEASE OR CONDITION, 2015
  • PLANNING AND RESPONSE TO BIOTERRORISM EVENT
    • FIGURE 1: FIVE COMPONENTS TO BIOLOGICAL DEFENSE (%)
• BIOSURVEILLANCE
• MICROBIAL FORENSICS
  • ROLE OF GOVERNMENT, UNIVERSITIES AND PRIVATE FUNDING IN PRODUCT DEVELOPMENT
    • TABLE 12: MAJOR GOVERNMENT FUNDERS OF R &D WITH AMOUNT FUNDED, 2012-2014 ($ BILLIONS)
    • FIGURE 2: U.S. GENERAL R &D FUNDING SOURCES, 2014 (%)
• FUNDING OPTIONS
  • U.S. GOVERNMENT FUNDING
    • Department of Homeland Security Project Biowatch
    • Department of Defense
  • UNIVERSITY/INDUSTRY FUNDING
• INDUSTRY CHANGES
  • TABLE 13: SELECTED MERGERS AND ACQUISITIONS IN THE BIODEFENSE IDENTIFICATION INDUSTRY, JANUARY 2013-JUNE 2015

CHAPTER 4 - OVERVIEW OF INFECTIOUS AGENTS

• TABLE 14: BIODEFENSE-RELATED PATHOGEN IDENTIFICATION WITH TEST AND TEST RESULT TIME (MINUTES)
• CATEGORY A BACTERIAL AGENTS
  • ANTHRAX
    • Signs and Symptoms
    • Detection Methods
      • TABLE 15: RAPID TESTS TO DETECT ANTHRAX
    • Vaccine Availability
    • Prevention/Treatment Protocols
  • PLAGUE (YERSINIA PESTIS)
    • Signs and Symptoms
    • Detection Methods
      • TABLE 16: RAPID TESTS TO DETECT YERSINIA PESTIS BACTERIA
    • Prevention/Treatment Protocols
  • TULAREMIA
    • Signs and Symptoms
    • Detection Methods
      • TABLE 17: RAPID TESTS TO DETECT FRANCISELLA TULARENSIS BACTERIA
    • Vaccine Availability
    • Prevention/Treatment Protocols
• CATEGORY A VIRAL AGENTS
  • SMALLPOX
    • Signs and Symptoms
    • Detection Methods
      • TABLE 18: RAPID TESTS TO DETECT SMALLPOX
    • Vaccine Availability
    • Prevention/Treatment Protocols
  • INFLUENZA
    • Signs and Symptoms
    • Detection Methods
      • TABLE 19: RAPID TESTS TO DETECT PANDEMIC INFLUENZA
    • Vaccine Availability
    • Prevention/Treatment Protocols
  • VIRAL HEMORRHAGIC FEVERS
    • Ebola Virus
    • Signs and Symptoms
    • Detection Methods
      • TABLE 20: RAPID TESTS TO DETECT EBOLA HEMORRHAGIC FEVER
    • Vaccine Availability
      • TABLE 21: VACCINES IN TESTING FOR EBOLA HEMORRHAGIC FEVER
    • Treatment Protocols
      • TABLE 22: PHARMACEUTICALS IN TESTING FOR EBOLA HEMORRHAGIC FEVER
    • Marburg Virus
    • Signs and Symptoms
    • Detection Methods
      • TABLE 23: RAPID TEST TO DETECT MARBURG HEMORRHAGIC FEVER
    • Vaccine Availability
    • Treatment Protocols
• CATEGORY B BACTERIAL AGENTS
  • BRUCELLOSIS
    • Signs and Symptoms
    • Detection Methods
      • TABLE 24: RAPID TESTS TO DETECT BRUCELLA
    • Vaccine Availability
    • Treatment Protocols
  • SALMONELLA
    • Signs and Symptoms
    • Detection Methods
      • TABLE 25: RAPID TESTS TO DETECT SALMONELLA
    • Vaccine Availability
    • Treatment Protocols
    • E. COLI
    • Signs and Symptoms
    • Detection Methods
      • TABLE 26: RAPID TESTS TO DETECT E. COLI
    • Vaccine Availability
    • Treatment Protocols
  • GLANDERS
    • Signs and Symptoms
    • Detection Methods
      • TABLE 27: RAPID TESTS TO DETECT GLANDERS
    • Vaccine Availability
    • Treatment Protocols
  • MELIOIDOSIS
    • Signs and Symptoms
    • Detection Methods
      • TABLE 28: RAPID TEST TO DETECT MELIOIDOSIS
    • Vaccine Availability
    • Treatment Protocols
  • PSITTACOSIS
    • Signs and Symptoms
    • Detection Methods
      • TABLE 29: RAPID TESTS TO DETECT PSITTACOSIS
    • Vaccine Availability
    • Treatment Protocols
  • Q FEVER
    • Signs and Symptoms
    • Detection Methods
      • TABLE 30: RAPID TESTS TO DETECT Q FEVER
    • Vaccine Availability
    • Treatment Protocols
  • STAPHYLOCOCCAL ENTEROTOXIN B (SEB)
    • Signs and Symptoms
    • Detection Methods
      • TABLE 31: RAPID TESTS TO DETECT SEB
    • Vaccine Availability
    • Treatment Protocols
  • TYPHOID FEVER
    • Signs and Symptoms
    • Detection Methods
      • TABLE 32: METHOD TO DETECT TYPHOID FEVER
    • Vaccine Availability
      • TABLE 33: VACCINES USED TO PREVENT TYPHOID INFECTIONS
    • Treatment Protocols
  • CHOLERA
    • Signs and Symptoms
    • Detection Methods
      • TABLE 34: RAPID TESTS TO DETECT CHOLERA
    • Vaccine Availability
    • Treatment Protocols
  • CRYPTOSPORIDIUM
    • Signs and Symptoms
    • Detection Methods
      • TABLE 35: METHODS TO DETECT CRYPTOSPORIDIUM
    • Vaccine Availability
    • Treatment
  • VIRAL ENCEPHALITIS
    • Signs and Symptoms
    • Detection Methods
      • TABLE 36: RAPID TESTS TO DETECT VIRAL ENCEPHALITIS
    • Vaccine Availability
    • Treatment Protocols
• CATEGORY B TOXINS
  • RICIN
    • Signs and Symptoms
    • Inhalation
    • Ingestion
    • Skin/Eye Exposure
    • Detection Methods
      • TABLE 37: RAPID TESTS TO DIAGNOSE RICIN POISONING
    • Vaccine Availability
    • Treatment Protocols
  • BOTULISM
    • Signs and Symptoms
    • Detection Methods
      • TABLE 38: RAPID TESTS TO DETECT BOTULISM POISONING
    • Vaccine Availability
      • TABLE 39: VACCINES TO TREAT BOTULISM
    • Treatment Protocols
    • VACCINE STOCKPILING
      • TABLE 40: U.S. GOVERNMENT CONTRACTED MARKET FOR SNS VACCINES, 2013-2018 ($ MILLIONS)
  • BIODEFENSE-RELATED VACCINE MARKET
    • TABLE 41: BIODEFENSE-RELATED VACCINES BY INDICATION, NAME AND MANUFACTURER
  • THERMOSTABLE VACCINES
• CLASSES OF DRUGS THAT EFFECTIVELY TREAT BIODEFENSE-RELATED PATHOGENS
  • AMINOGLYCOSIDES
  • QUINOLONES
  • TETRACYCLINES
    • TABLE 42: MEDICATIONS TO TREAT SELECTED BIODEFENSE-RELATED PATHOGENS BY DISEASE, MEDICATION AND TYPE
    • FIGURE 3: ANTIBIOTICS USED TO TREAT BIODEFENSE-RELATED BACTERIAL THREATS (%)
  • BARRIERS TO USING BIOLOGICAL WEAPONS
    • TABLE 43: BARRIERS TO USING BIOLOGICAL WEAPONS

CHAPTER 5 - BIODEFENSE-RELATED PATHOGEN DETECTION DEVICES

• TABLE 44: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN DETECTION DEVICES, THROUGH 2021 ($ MILLIONS)
• PATHOGEN ID DEVICES BY TESTING METHOD
  • TABLE 45: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TESTING METHOD, THROUGH 2021 ($ MILLIONS)
  • FIGURE 4: SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TESTING METHOD, 2016 AND 2021 (%)
• TYPE OF DEVICE
  • TABLE 46: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TYPE, THROUGH 2021 ($ MILLIONS)
  • FIGURE 5: SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TYPE, 2016 AND 2021 (%)
• DIAGNOSTIC TOOLS
  • MASS SPECTROMETRY
    • TABLE 47: PROJECTED BIODEFENSE-RELATED MASS SPECTROMETRY DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • PCR
    • TABLE 48: PROJECTED BIODEFENSE-RELATED PCR DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • IMMUNOLOGICAL ANALYSIS
    • TABLE 49: PROJECTED U.S. BIODEFENSE-RELATED IMMUNOLOGICAL DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
• BIOLOGICAL SENSORS
  • CELLULAR ANALYSIS AND NOTIFICATION OF ANTIGEN RISKS AND YIELDS (CANARY)
  • PHOTONIC SENSORS
  • FIBER-OPTIC BIOSENSORS
  • LAB-ON-CHIP BIOSENSORS
• THE BIODEFENSE BIOSENSOR MARKET
  • TABLE 50: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED BIOLOGICAL SENSORS, THROUGH 2021 ($ MILLIONS)

CHAPTER 6 - CURRENT RESEARCH, EMERGING THERAPIES, PATENTS AND MARKET OPPORTUNITIES

• PHARMACEUTICAL TREATMENT PRODUCT PIPELINE
  • TABLE 51: PATHOGEN PHARMACEUTICAL PRODUCT PIPELINE
• PHARMACEUTICAL RESEARCH
  • BACTERIAL INFECTIONS: PRODUCTS IN DEVELOPMENT
    • Rapid Test for Plague
    • BARDA's Antibacterial Program
      • TABLE 52: PHARMACEUTICALS IN BACTERIA BIOTHREAT PIPELINE BY COMPOUND NAME, STAGE OF DEVELOPMENT, APPLICATION, AND DEVELOPER
  • VIRAL INFECTIONS: PRODUCTS IN DEVELOPMENT
    • BioCryst Pharmaceuticals
    • Toyama Chemical
  • TOXIN RESEARCH
    • Gene Therapy Treatment for Botulism
• VACCINE RESEARCH
  • LAWRENCE LIVERMORE NATIONAL LABORATORY (LLNL)
  • ORGANIC VACCINES
  • PROFECTUS BIOSCIENCES
  • SOLIGENIX
  • TULANE UNIVERSITY (NEW ORLEANS, LA.)
• PATHOGEN VACCINE PIPELINE
  • TABLE 53: PANDEMIC VACCINES UNDER DEVELOPMENT, 2015
• VIRAL PRODUCT RESEARCH
  • AUTOIMMUNE TECHNOLOGIES
• BIODEFENSE-RELATED DEVICE RESEARCH
  • OMNI ARRAY BIOTECHNOLOGY
  • NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (BEIJING, CHINA)
  • BIOSENSORS USED IN SMARTPHONES
  • ANTHRAX DETECTION
  • I-DIAGNOSTICS AND TIRF LABS
  • GEORGIA TECH RESEARCH INSTITUTE
  • CARBON NANOTUBE THIN FILM BIOSENSORS FOR WHOLE VIRUS DETECTION
  • MOLYBDENUM DISULFIDE BIOSENSORS
• PATENTS
  • PATENTS BY NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION, DATE OF ISSUE
    • TABLE 54: RAPID PATHOGEN IDENTIFICATION PATENTS: NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION AND DATE OF ISSUE, AUGUST 2011-JUNE 2015
  • PATENTS BY MANUFACTURER
    • TABLE 55: NUMBER OF PATENTS BY MANUFACTURER, AUGUST 2011-JUNE 2015
    • TABLE 56: PATENTS BY FUNCTION AND COMPANY AUGUST 2011-JUNE 2015
• PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES
• VACCINE MARKET OPPORTUNITIES/CHALLENGES
• DEVICE MARKET OPPORTUNITIES/CHALLENGES
  • CHALLENGES
  • OPPORTUNITIES
    • Rapid Assays
• THE IMPACT OF GLOBAL POLITICAL/SOCIETAL CHANGES
• SOCIETAL CHANGES

CHAPTER 7 - U.S. AGENCIES AND THEIR PURPOSES

• UNITED STATES DISEASE STRATEGY
  • TABLE 57: SELECTED EMERGING INFECTIOUS DISEASE SINCE 1975 BY NAME, YEAR IDENTIFIED, ESTIMATED GLOBAL IMPACT AND MORTALITY PERCENTAGE
• DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
  • PROJECT BIOSHIELD
    • FIGURE 6: PERCENTAGE OF PROJECT BIOSHIELD FUNDS USED TO ACQUIRE COUNTERMEASURES, 2004-2014 (%)
  • PANDEMIC AND ALL-HAZARDS PREPAREDNESS REAUTHORIZATION
    • Pandemic and All-Hazards Preparedness Reauthorization Act of 2013
      • Title I: Strengthening Preparedness and Response for Public Health Emergencies
      • Title II: Optimizing State and Local All-Hazards Preparedness and Response
      • Title III: Enhancing Medical Countermeasure Review
      • Title IV: Accelerating Medical Countermeasure Advanced Research and Development
    • BARDA
  • CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
  • NATIONAL INSTITUTES OF HEALTH (NIH)
  • U.S. FOOD AND DRUG ADMINISTRATION (FDA)
  • FOOD SAFETY AND MODERNIZATION ACT (FSMA)
    • Key Initiatives of the Legislation
    • Prevention
    • Enhanced Partnerships

CHAPTER 8 - COMPANY DIRECTORY

• DIAGNOSTIC PRODUCTS
  • 20/20 GENESYSTEMS, INC.
    • Business Overview
    • Product
      • TABLE 58: 20/20 DIAGNOSTIC PRODUCT
  • ADVNT BIOTECHNOLOGIES
    • Business Overview
    • Products
      • TABLE 59: ADVNT DETECTION PRODUCTS
  • AETHLON MEDICAL
    • Business Overview
    • Products
      • TABLE 60: AETHLON MEDICAL PRODUCTS
  • ALERE
    • Business Overview
    • Products
      • TABLE 61: ALERE DIAGNOSTIC PRODUCTS
  • ALEXETER TECHNOLOGIES
    • Business Overview
    • Products
      • TABLE 62: ALEXETER TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • ALPHA DIAGNOSTIC INTERNATIONAL
    • Business Overview
    • Products
      • TABLE 63: ALPHA DIAGNOSTIC INTERNATIONAL DIAGNOSTIC PRODUCTS
  • ANP TECHNOLOGIES
    • Business Overview
    • Products
      • TABLE 64: ANP TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • ATLAS LINK BIOTECH CO., LTD
    • Business Overview
    • Products
      • TABLE 65: ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS
  • BATTELLE
    • Business Overview
    • Products
      • TABLE 66: BATTELLE DIAGNOSTIC PRODUCTS
  • BB DETECTION
    • Business Overview
    • Product
      • TABLE 67: BB DETECTION DIAGNOSTIC PRODUCT
  • BERTIN TECHNOLOGIES
    • Business Overview
    • Products
      • TABLE 68: BERTIN TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • BIODETECTION INSTRUMENTS
    • Business Overview
    • Product
      • TABLE 69: BIODETECTION INSTRUMENTS DIAGNOSTIC PRODUCT
  • BIOFIRE DEFENSE
    • Business Overview
    • Products
      • TABLE 70: BIOFIRE DEFENSE PRODUCTS
  • BIOMEME
    • Business Overview
    • Product
      • TABLE 71: BIOMEME BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • BIOMERIEUX, INC.
    • Business Overview
    • Products
      • TABLE 72: BIOMERIEUX BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • BIOSEARCH TECHNOLOGIES
    • Business Overview
    • Product
      • TABLE 73: BIOSEARCH TECHNOLOGIES DIAGNOSTIC PRODUCT
  • BIOTECH INTERNATIONAL
    • Business Overview
    • Product
      • TABLE 74: BIOTECH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • BRUKER DETECTION
    • Business Overview
    • Product
      • TABLE 75: BRUKER BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • CANGENE CORP. (SEE EMERGENT BIOSOLUTIONS)
  • CERES NANOSCIENCES, INC.
    • Business Overview
  • CHEMRING DETECTION SYSTEMS
    • Business Overview
    • Product
      • TABLE 76: CHEMRING BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • CORGENIX MEDICAL CORP
    • Business Overview
    • Product
      • TABLE 77: CORGENIX DIAGNOSTIC PRODUCT
  • DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
    • Business Overview
      • TABLE 78: DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • DIATHERIX
    • Business Overview
    • Product
      • TABLE 79: DIATHERIX DIAGNOSTIC PRODUCT
  • ELECTRONIC SENSOR TECHNOLOGY, INC.
    • Business Overview
    • Product
      • TABLE 80: ELECTRONIC SENSOR TECHNOLOGY DIAGNOSTIC PRODUCT
  • ENVIRONICS OY
    • Business Overview
    • Products
      • TABLE 81: ENVIRONICS DIAGNOSTICS PRODUCTS
  • HAZTECH SYSTEMS
    • Business Overview
    • Products
      • TABLE 82: HAZTECH BIODEFENSE-RELATED PRODUCTS
  • INBIOS INTERNATIONAL, INC.
    • Business Overview
    • Products
      • TABLE 83: INBIOS DIAGNOSTICS PRODUCTS
  • INTEGRATED NANO-TECHNOLOGIES
    • Business Overview
    • Product
      • TABLE 84: INTEGRATED NANO-TECHNOLOGIES DIAGNOSTICS PRODUCT
  • MENON BIOSENSORS, INC.
    • Business Overview
    • Product
      • TABLE 85: MENON BIOSENSORS DIAGNOSTIC PRODUCT
  • MESO SCALE DEFENSE
    • Business Overview
    • Products
      • TABLE 86: MESO SCALE DEFENSE DIAGNOSTICS PRODUCTS
  • NANOLOGIX
    • Business Overview
    • Product
      • TABLE 87: NANOLOGIX DIAGNOSTICS PRODUCT
  • NEW HORIZON DIAGNOSTIC CORP.
    • Business Overview
    • Products
      • TABLE 88: NEW HORIZON DIAGNOSTICS PRODUCTS
  • OXFORD NANOPORE TECHNOLOGIES, LTD.
    • Business Overview
    • Products
      • TABLE 89: OXFORD NANOPORE TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • PATHSENSORS, INC.
    • Business Overview
    • Products
      • TABLE 90: PATHSENSORS DIAGNOSTICS PRODUCTS
  • POSITIVE ID CORP.
    • Business Overview
    • Products
      • TABLE 91: POSITIVE ID DIAGNOSTICS PRODUCTS
  • PROENGIN, INC.
    • Business Overview
    • Product
      • TABLE 92: PROENGIN DIAGNOSTICS PRODUCT
  • QIAGEN N.V.
    • Business Overview
    • Products
      • TABLE 93: QIAGEN BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • QUANTUMDX GROUP
    • Business Overview
    • Product
      • TABLE 94: QUANTUMDX BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • RESEARCH INTERNATIONAL, INC.
    • Business Overview
    • Product
      • TABLE 95: RESEARCH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • REAL-TIME ANALYZERS, INC.
    • Business Overview
    • Product
      • TABLE 96: REAL-TIME ANALYZERS DIAGNOSTIC PRODUCT
  • RESPONSE BIOMEDICAL CORP.
    • Business Overview
    • Products
      • TABLE 97: RESPONSE BIOMEDICAL DIAGNOSTIC PRODUCTS
  • SANDIA NATIONAL LABORATORIES
    • Business Overview
    • Product
      • TABLE 98: SANDIA NATIONAL LABORATORIES DIAGNOSTIC PRODUCT
  • SMITHS DETECTION
    • Business Overview
    • Products
      • TABLE 99: SMITHS DETECTION BIODEFENSE-RELATED PRODUCTS
  • THERMO FISHER
    • Business Overview
    • Product
      • TABLE 100: THERMO FISHER BIODEFENSE-RELATED PRODUCT
  • TETRACORE
    • Business Overview
    • Products
      • TABLE 101: TETRACORE BIODEFENSE-RELATED PRODUCTS
  • VACCINES
  • BAVARIAN NORDIC A/S
    • Business Overview
    • Product
      • TABLE 102: BAVARIAN NORDIC BIODEFENSE VACCINE PRODUCT
  • CRUCELL HOLLAND B.V.
    • Business Overview
  • EMERGENT BIOSOLUTIONS
    • Business Overview
    • Products
      • TABLE 103: EMERGENT BIOSOLUTIONS VACCINE PRODUCTS
  • INOVIO PHARMCEUTICALS
    • Business Overview
    • Products
      • TABLE 104: INOVIO PHARMACEUTICALS VACCINE PRODUCTS
  • NOVAVAX
    • Business Overview
    • Products
      • TABLE 105: NOVAVAX VACCINE PRODUCTS
  • PHARMATHENE, INC.
    • Business Overview
    • Products
      • TABLE 106: PHARMATHENE VACCINE PRODUCTS
  • SOLIGENIX
    • Business Overview
  • TAPIMMUNE
    • Business Overview
  • PHARMACEUTICALS
  • GLAXOSMITHKLINE
    • Business Overview
    • Products
      • TABLE 107: GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS
  • MERCK
    • Business Overview
    • Products
      • TABLE 108: MERCK BIODEFENSE-RELATED PHARMACEUTICAL PRODUCTS
  • SAREPTA THERAPEUTICS
    • Business Overview
  • SIGA TECHNOLOGIES
    • Business Overview
    • Product
      • TABLE 109: SIGA BIODEFENSE-RELATED PRODUCT
• NATIONAL LABORATORIES
  • LAWRENCE LIVERMORE NATIONAL LABORATORIES
    • Business Overview
  • SABIN VACCINE INSTITUTE
    • Business Overview

LIST OF TABLES

• SUMMARY TABLE: U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 1: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS A
  • TABLE 2: CLASS A PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
  • TABLE 3: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS B
  • TABLE 4: CLASS B PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
  • TABLE 5: U.S. GOVERNMENT CLASSIFICATION OF BIOTERRORISM AGENTS/DISEASES: CLASS C
  • TABLE 6: CLASS C PATHOGEN IDENTIFICATION BY TRANSMISSION METHOD
  • TABLE 7: LIMITATIONS OF SOME COMMON ANALYSIS METHODS
  • TABLE 8: CHARACTERISTICS OF BIOSENSORS
  • TABLE 9: DETECT-TO-WARN MONITORING SYSTEMS
  • TABLE 10: VACCINES FOR PATHOGENS, BY DISEASE OR CONDITION, BRAND NAME AND MANUFACTURER, 2014
  • TABLE 11: COMMON PHARMACEUTICALS TO TREAT BIODEFENSE-RELATED PATHOGENS BY NAME, MANUFACTURER, DISEASE OR CONDITION, 2015
  • TABLE 12: MAJOR GOVERNMENT FUNDERS OF R &D WITH AMOUNT FUNDED, 2012-2014 ($ BILLIONS)
  • TABLE 13: SELECTED MERGERS AND ACQUISITIONS IN THE BIODEFENSE IDENTIFICATION INDUSTRY, JANUARY 2013-JUNE 2015
  • TABLE 14: BIODEFENSE-RELATED PATHOGEN IDENTIFICATION WITH TEST AND TEST RESULT TIME (MINUTES)
  • TABLE 15: RAPID TESTS TO DETECT ANTHRAX
  • TABLE 16: RAPID TESTS TO DETECT YERSINIA PESTIS BACTERIA
  • TABLE 17: RAPID TESTS TO DETECT FRANCISELLA TULARENSIS BACTERIA
  • TABLE 18: RAPID TESTS TO DETECT SMALLPOX
  • TABLE 19: RAPID TESTS TO DETECT PANDEMIC INFLUENZA
  • TABLE 20: RAPID TESTS TO DETECT EBOLA HEMORRHAGIC FEVER
  • TABLE 21: VACCINES IN TESTING FOR EBOLA HEMORRHAGIC FEVER
  • TABLE 22: PHARMACEUTICALS IN TESTING FOR EBOLA HEMORRHAGIC FEVER
  • TABLE 23: RAPID TEST TO DETECT MARBURG HEMORRHAGIC FEVER
  • TABLE 24: RAPID TESTS TO DETECT BRUCELLA
  • TABLE 25: RAPID TESTS TO DETECT SALMONELLA
  • TABLE 26: RAPID TESTS TO DETECT E. COLI
  • TABLE 27: RAPID TESTS TO DETECT GLANDERS
  • TABLE 28: RAPID TEST TO DETECT MELIOIDOSIS
  • TABLE 29: RAPID TESTS TO DETECT PSITTACOSIS
  • TABLE 30: RAPID TESTS TO DETECT Q FEVER
  • TABLE 31: RAPID TESTS TO DETECT SEB
  • TABLE 32: METHOD TO DETECT TYPHOID FEVER
  • TABLE 33: VACCINES USED TO PREVENT TYPHOID INFECTIONS
  • TABLE 34: RAPID TESTS TO DETECT CHOLERA
  • TABLE 35: METHODS TO DETECT CRYPTOSPORIDIUM
  • TABLE 36: RAPID TESTS TO DETECT VIRAL ENCEPHALITIS
  • TABLE 37: RAPID TESTS TO DIAGNOSE RICIN POISONING
  • TABLE 38: RAPID TESTS TO DETECT BOTULISM POISONING
  • TABLE 39: VACCINES TO TREAT BOTULISM
  • TABLE 40: U.S. GOVERNMENT CONTRACTED MARKET FOR SNS VACCINES, 2013-2018 ($ MILLIONS)
  • TABLE 41: BIODEFENSE-RELATED VACCINES BY INDICATION, NAME AND MANUFACTURER
  • TABLE 42: MEDICATIONS TO TREAT SELECTED BIODEFENSE-RELATED PATHOGENS BY DISEASE, MEDICATION AND TYPE
  • TABLE 43: BARRIERS TO USING BIOLOGICAL WEAPONS
  • TABLE 44: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED RAPID PATHOGEN DETECTION DEVICES, THROUGH 2021 ($ MILLIONS)
  • TABLE 45: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TESTING METHOD, THROUGH 2021 ($ MILLIONS)
  • TABLE 46: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED DETECTION DEVICES BY TYPE, THROUGH 2021 ($ MILLIONS)
  • TABLE 47: PROJECTED BIODEFENSE-RELATED MASS SPECTROMETRY DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 48: PROJECTED BIODEFENSE-RELATED PCR DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 49: PROJECTED U.S. BIODEFENSE-RELATED IMMUNOLOGICAL DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 50: PROJECTED U.S. MARKET FOR BIODEFENSE-RELATED BIOLOGICAL SENSORS, THROUGH 2021 ($ MILLIONS)
  • TABLE 51: PATHOGEN PHARMACEUTICAL PRODUCT PIPELINE
  • TABLE 52: PHARMACEUTICALS IN BACTERIA BIOTHREAT PIPELINE BY COMPOUND NAME, STAGE OF DEVELOPMENT, APPLICATION, AND DEVELOPER
  • TABLE 53: PANDEMIC VACCINES UNDER DEVELOPMENT, 2015
  • TABLE 54: RAPID PATHOGEN IDENTIFICATION PATENTS: NUMBER, COMPANY, TYPE OF DEVICE, DESCRIPTION AND DATE OF ISSUE, AUGUST 2011-JUNE 2015
  • TABLE 55: NUMBER OF PATENTS BY MANUFACTURER, AUGUST 2011-JUNE 2015
  • TABLE 56: PATENTS BY FUNCTION AND COMPANY AUGUST 2011-JUNE 2015
  • TABLE 57: SELECTED EMERGING INFECTIOUS DISEASE SINCE 1975 BY NAME, YEAR IDENTIFIED, ESTIMATED GLOBAL IMPACT AND MORTALITY PERCENTAGE
  • TABLE 58: 20/20 DIAGNOSTIC PRODUCT
  • TABLE 59: ADVNT DETECTION PRODUCTS
  • TABLE 60: AETHLON MEDICAL PRODUCTS
  • TABLE 61: ALERE DIAGNOSTIC PRODUCTS
  • TABLE 62: ALEXETER TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • TABLE 63: ALPHA DIAGNOSTIC INTERNATIONAL DIAGNOSTIC PRODUCTS
  • TABLE 64: ANP TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • TABLE 65: ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS
  • TABLE 66: BATTELLE DIAGNOSTIC PRODUCTS
  • TABLE 67: BB DETECTION DIAGNOSTIC PRODUCT
  • TABLE 68: BERTIN TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • TABLE 69: BIODETECTION INSTRUMENTS DIAGNOSTIC PRODUCT
  • TABLE 70: BIOFIRE DEFENSE PRODUCTS
  • TABLE 71: BIOMEME BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • TABLE 72: BIOMERIEUX BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • TABLE 73: BIOSEARCH TECHNOLOGIES DIAGNOSTIC PRODUCT
  • TABLE 74: BIOTECH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • TABLE 75: BRUKER BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • TABLE 76: CHEMRING BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • TABLE 77: CORGENIX DIAGNOSTIC PRODUCT
  • TABLE 78: DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS
  • TABLE 79: DIATHERIX DIAGNOSTIC PRODUCT
  • TABLE 80: ELECTRONIC SENSOR TECHNOLOGY DIAGNOSTIC PRODUCT
  • TABLE 81: ENVIRONICS DIAGNOSTICS PRODUCTS
  • TABLE 82: HAZTECH BIODEFENSE-RELATED PRODUCTS
  • TABLE 83: INBIOS DIAGNOSTICS PRODUCTS
  • TABLE 84: INTEGRATED NANO-TECHNOLOGIES DIAGNOSTICS PRODUCT
  • TABLE 85: MENON BIOSENSORS DIAGNOSTIC PRODUCT
  • TABLE 86: MESO SCALE DEFENSE DIAGNOSTICS PRODUCTS
  • TABLE 87: NANOLOGIX DIAGNOSTICS PRODUCT
  • TABLE 88: NEW HORIZON DIAGNOSTICS PRODUCTS
  • TABLE 89: OXFORD NANOPORE TECHNOLOGIES DIAGNOSTIC PRODUCTS
  • TABLE 90: PATHSENSORS DIAGNOSTICS PRODUCTS
  • TABLE 91: POSITIVE ID DIAGNOSTICS PRODUCTS
  • TABLE 92: PROENGIN DIAGNOSTICS PRODUCT
  • TABLE 93: QIAGEN BIODEFENSE-RELATED DIAGNOSTIC PRODUCTS
  • TABLE 94: QUANTUMDX BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • TABLE 95: RESEARCH INTERNATIONAL BIODEFENSE-RELATED DIAGNOSTIC PRODUCT
  • TABLE 96: REAL-TIME ANALYZERS DIAGNOSTIC PRODUCT
  • TABLE 97: RESPONSE BIOMEDICAL DIAGNOSTIC PRODUCTS
  • TABLE 98: SANDIA NATIONAL LABORATORIES DIAGNOSTIC PRODUCT
  • TABLE 99: SMITHS DETECTION BIODEFENSE-RELATED PRODUCTS
  • TABLE 100: THERMO FISHER BIODEFENSE-RELATED PRODUCT
  • TABLE 101: TETRACORE BIODEFENSE-RELATED PRODUCTS
  • TABLE 102: BAVARIAN NORDIC BIODEFENSE VACCINE PRODUCT
  • TABLE 103: EMERGENT BIOSOLUTIONS VACCINE PRODUCTS
  • TABLE 104: INOVIO PHARMACEUTICALS VACCINE PRODUCTS
  • TABLE 105: NOVAVAX VACCINE PRODUCTS
  • TABLE 106: PHARMATHENE VACCINE PRODUCTS
  • TABLE 107: GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS
  • TABLE 108: MERCK BIODEFENSE-RELATED PHARMACEUTICAL PRODUCTS
  • TABLE 109: SIGA BIODEFENSE-RELATED PRODUCT

LIST OF FIGURES

• SUMMARY FIGURE: BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION MARKET, BY TYPE OF DETECTION, IN 2016 AND 2021 (%)
  • FIGURE 1: FIVE COMPONENTS TO BIOLOGICAL DEFENSE (%)
  • FIGURE 2: U.S. GENERAL R &D FUNDING SOURCES, 2014 (%)
  • FIGURE 3: ANTIBIOTICS USED TO TREAT BIODEFENSE-RELATED BACTERIAL THREATS (%)
  • FIGURE 4: SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TESTING METHOD, 2016 AND 2021 (%)
  • FIGURE 5: SHARES OF BIODEFENSE-RELATED RAPID PATHOGEN IDENTIFICATION DEVICES BY TYPE, 2016 AND 2021 (%)
  • FIGURE 6: PERCENTAGE OF PROJECT BIOSHIELD FUNDS USED TO ACQUIRE COUNTERMEASURES, 2004-2014 (%) 102